Tim M. Mayleben
2017 - Esperion Therapeutics
In 2017, Tim M. Mayleben earned a total compensation of $5M as President and Chief Executive Officer at Esperion Therapeutics, a 313% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $404,000 |
|---|---|
| Option Awards | $3,962,187 |
| Salary | $557,500 |
| Other | $89,773 |
| Total | $5,013,460 |
Mayleben received $4M in option awards, accounting for 79% of the total pay in 2017.
Mayleben also received $404K in non-equity incentive plan, $557.5K in salary and $89.8K in other compensation.
Rankings
In 2017, Tim M. Mayleben's compensation ranked 1,888th out of 14,666 executives tracked by ExecPay. In other words, Mayleben earned more than 87.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,888 out of 14,666 | 87th |
Division Manufacturing | 635 out of 5,768 | 89th |
Major group Chemicals And Allied Products | 169 out of 2,074 | 92nd |
Industry group Drugs | 124 out of 1,730 | 93rd |
Industry Pharmaceutical Preparations | 94 out of 1,329 | 93rd |
Source: SEC filing on April 13, 2018.
Mayleben's colleagues
We found two more compensation records of executives who worked with Tim M. Mayleben at Esperion Therapeutics in 2017.
News
Landos Biopharma CEO Gregory Oakes receives $1.8M in 2022
April 19, 2023
Landos Biopharma Executive Vice President of Operations Jyoti RAC's 2021 pay jumps 195% to $2.8M
April 28, 2022
Esperion Therapeutics CEO Tim Mayleben's 2021 pay rises 19% to $8.2M
April 14, 2022
Esperion Therapeutics CEO Tim Mayleben's 2019 pay falls 89% to $1.1M
April 16, 2020
Esperion Therapeutics CEO Tim Mayleben's 2018 pay jumps 94% to $9.7M
April 18, 2019